Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Total Non-Current Liabilities (2016 - 2020)

Historic Total Non-Current Liabilities for International Stem Cell (ISCO) over the last 12 years, with Q3 2020 value amounting to $5.4 million.

  • International Stem Cell's Total Non-Current Liabilities changed N/A to $5.4 million in Q3 2020 from the same period last year, while for Sep 2020 it was $5.4 million, marking a year-over-year change of. This contributed to the annual value of $5.0 million for FY2019, which is 4231.64% up from last year.
  • Per International Stem Cell's latest filing, its Total Non-Current Liabilities stood at $5.4 million for Q3 2020.
  • In the past 5 years, International Stem Cell's Total Non-Current Liabilities registered a high of $5.8 million during Q2 2020, and its lowest value of $1.6 million during Q4 2016.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $3.7 million (2017), whereas its average is $3.6 million.
  • In the last 5 years, International Stem Cell's Total Non-Current Liabilities plummeted by 7066.92% in 2016 and then skyrocketed by 16367.92% in 2017.
  • Over the past 5 years, International Stem Cell's Total Non-Current Liabilities (Quarter) stood at $1.6 million in 2016, then grew by 8.42% to $1.7 million in 2017, then skyrocketed by 108.3% to $3.5 million in 2018, then skyrocketed by 42.32% to $5.0 million in 2019, then increased by 7.72% to $5.4 million in 2020.
  • Its last three reported values are $5.4 million in Q3 2020, $5.8 million for Q2 2020, and $5.3 million during Q1 2020.